Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
January 04 2023 - 7:00AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the
“Company”), a clinical-stage biopharmaceutical company focused on
the development of novel targeted therapeutics for Alzheimer’s
disease (AD), today announced Derrell Porter, M.D., has joined its
Board of Directors.
“We are thrilled to welcome Dr. Porter to our
Board of Directors at a time when we’re rapidly advancing clinical
development of ACU193,” said Daniel O’Connell, President and Chief
Executive Officer of Acumen Pharmaceuticals. “Dr. Porter brings
significant expertise in drug development and commercialization to
the Board as we develop a novel and potentially disease-modifying
treatment for Alzheimer’s disease. His deep experience in diseases
that benefit from personalized treatments and combination therapies
will be invaluable to Acumen.”
Dr. Porter said: “This is an exciting time for
drug development in Alzheimer’s disease, and I am drawn to Acumen’s
pioneering science and the therapeutic promise of ACU193. I look
forward to contributing my experience bringing meaningful
treatments to market as Acumen works to deliver therapies that can
substantially impact those affected by this devastating
disease.”
Dr. Porter is a physician-entrepreneur with more
than 20 years of experience in drug development. He is currently
the Founder and CEO of Cellevolve, a development and
commercialization cell therapy biotech focused on neglected
diseases, and previously served in commercial and corporate
development roles at Atara Bio, Gilead, AbbVie and Amgen. He is
also a Board Member at Passage Bio, a genetics medicine company
developing therapeutics for disorders of the central nervous
system; Portal Innovations, LLC, a venture development engine which
delivers seed capital, specialized equipment, lab space, and
management expertise to early-stage biotech companies; and an
Advisory Committee Member at the University of Pennsylvania School
of Medicine.
Dr. Porter started his career at McKinsey &
Company. He earned his M.D. from the Perelman School of Medicine
and MBA from the Wharton School at the University of Pennsylvania,
and his B.S. in Neuroscience from the University of California, Los
Angeles.
About ACU193
ACU193 is a humanized monoclonal antibody (mAb)
discovered and developed based on its selectivity for soluble AβOs,
which Acumen believes are the most toxic and pathogenic form of Aβ,
relative to Aβ monomers and amyloid plaques. Soluble AβOs have been
observed to be potent neurotoxins that bind to neurons, inhibit
synaptic function and induce neurodegeneration. By selectively
targeting toxic soluble AβOs, ACU193 aims to directly address what
a growing body of evidence indicates is a primary underlying cause
of the neurodegenerative process in AD. ACU193 has been granted
Fast Track designation for the treatment of early Alzheimer’s
disease by the U.S. Food and Drug Administration.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA,
with clinical operations based in Carmel, IN, is a clinical stage
biopharmaceutical company developing a novel disease-modifying
approach to treat Alzheimer’s disease. Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are primary triggers of Alzheimer’s disease pathology.
Acumen is currently focused on advancing its investigational
product candidate, ACU193, a humanized monoclonal antibody that
selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1
clinical trial involving early Alzheimer’s disease patients. For
more information, visit www.acumenpharm.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Any statement describing Acumen’s goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Words such as “believes,” “expects,” “anticipates,”
“could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,”
“will,” “milestone” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements include the those concerning the
therapeutic potential of Acumen’s product candidate, ACU193. These
statements are based upon the current beliefs and expectations of
Acumen management, and are subject to certain factors, risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing safe and effective
human therapeutics. Such risks may be amplified by the impacts of
the COVID-19 pandemic, geopolitical events and macroeconomic
conditions, such as rising inflation and interest rates, supply
disruptions and uncertainty of credit and financial markets. These
and other risks concerning Acumen’s programs are described in
additional detail in Acumen’s filings with the Securities and
Exchange Commission (“SEC”), including in Acumen’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2021, and future
filings with the SEC, including Acumen’s Quarterly Report on Form
10-Q for the quarter ended and September 30, 2022. Copies of these
and other documents are available from Acumen. Additional
information will be made available in other filings that Acumen
makes from time to time with the SEC. These forward-looking
statements speak only as of the date hereof, and Acumen expressly
disclaims any obligation to update or revise any forward-looking
statement, except as otherwise required by law, whether, as a
result of new information, future events or otherwise.
Investors:Alex Braunabraun@acumenpharm.com
Media:AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2024 to May 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From May 2023 to May 2024